BiotechTube
NVIGEN

NVIGEN

San Jose, United States· Est.
nvigen.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2M

Overview

NVIGEN is a private, nanotechnology-focused biotech company developing a suite of products and assays centered on its patented MagVigen™ and related nanoparticle platforms. Its core business model spans Diagnostics and Platform tools, offering research-use products like magnetic beads for sample preparation while advancing its NVIGEN X® liquid biopsy assay toward clinical development for cancer recurrence prediction and therapy guidance. The company is in an Early Revenue stage, commercializing research kits and services while investing in its clinical pipeline, which is currently in the Pre-clinical/development phase.

OncologyInfectious Diseases

Technology Platform

Proprietary multifunctional, biodegradable magnetic and fluorescent nanoparticles (MagVigen™, MyQuVigen™, MaxVigen™) used for sample preparation, assay development, multi-omics biomarker profiling, drug delivery, and cell therapy enhancement.

Funding History

2
Total raised:$2M
Grant$500K
Seed$1.5M

Opportunities

The growing liquid biopsy market demands comprehensive multi-analyte tests, which NVIGEN X® aims to provide.
Successfully obtaining FDA approval would allow deployment in clinical settings, tapping into the large precision oncology diagnostics market.
The research tools business provides a steady revenue stream and platform validation.

Risk Factors

High risk in clinically validating and obtaining regulatory approval for its flagship NVIGEN X® assay.
Intense competition in both the research consumables and clinical diagnostics markets from well-capitalized players.
Dependency on future fundraising to finance expensive clinical and regulatory pathways.

Competitive Landscape

In research products, competes with large life science tools companies (e.g., Thermo Fisher, Merck) and bead-based specialists. In clinical diagnostics, future competition includes established liquid biopsy leaders (e.g., Guardant Health, FOUNDATION Medicine) and other multi-omics startups. Differentiation hinges on its proprietary nanoparticle technology's performance and integration capabilities.

More companies in Drug Delivery & Formulation →More companies in United States →